Applications
Spheroids for Drug Testing - 3D Cell-based Assays
Click here, to read the PDF-file
(pdf-file 325.41 KB)Drug discovery is risky, costly and time consuming. Thus, selection criteria reliably identifying promising drug candidates in early drug development are needed. Because empirical drug testing in simple preclinical models including subcutaneous mice is not sufficient for translation into the clinic, high content (HC) assays reflecting complexity and heterogeneity of patient tumors are required for high quality results. Moreover, these HC models have to be adaptive for high-throughput (HT) drug testing.
Authors:
PD Dr. Barbara Mayer et al., SpheroTec
Related Articles :
- The European Lab Automation Conference and Exhibition 2012
- Cloud Computing and Genomics and How They can be Combined
- Annual Report to the Nation on the Status of Cancer: Cancer Death Rates Decline in the United States
- Droplet-based Microfluidics: Sensitive Detection of Rare Mutations
- Carbon Nanoparticles may Enhance Cancer Therapy
Keywords : 3D Cell-based Assays Anita Wagner Barbara Mayer Cancer Cancer Therapy Cytometry Drug Development Drug Discovery Drug Testing FACS HC test system heterotypic spheroid model High Content Assay High Content Screening high-throughput drug testing homotypic spheroid model Ilona Funke Karin von Dehn-Rotfelser Oncology Preclinical Model Screening Screening Application Note Spheroid Model Spheroids Stefanie Magosch subcutaneous mice Therapeutics Tumor
Email requestCompany HomepageSpheroTec GmbH
Am Klopferspitz 19
82152 Planegg
Germany
Tel: +49 89 540 41 34-0
Fax: +49 89 540 41 34-20
Web: http://www.spherotec.com
- Legal
- Help
- Participate
- Related Publications
Reader comments (0)